ロード中...
CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro
Immune checkpoint inhibitors targeting coinhibitory pathways in T cells possess efficacy in combating cancer. In addition to PD-1/PD-L1 and CTLA-4 antibodies which are already established in tumor immunotherapy, immune checkpoints such as LAG-3 or BTLA are emerging, which may have the potential to e...
保存先:
| 出版年: | Cancer Immunol Immunother |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683241/ https://ncbi.nlm.nih.gov/pubmed/31332464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02369-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|